ライフサイエンスコーパス: IL-10 receptor

1 sis of the interaction between IL-10 and the IL-10 receptor.

2 -10-mediated effects and is a subunit of the IL-10 receptor.

3 Ba/F3 cells that stably expressed the murine IL-10 receptor.

4 histochemistry that cortical neurons express IL-10 receptor.

5 odies specific for interleukin-10 (IL-10) or IL-10 receptor.

6 production from microglial cells through the IL-10 receptor.

7 n of KC, even though the cells expressed the IL-10 receptor.

8 ingle-nucleotide polymorphisms (SNPs) in the IL-10 receptor 1 (IL10R1) gene.

9 ithin the YXXQ-STAT3-docking site within the IL-10 receptor 1 and that no other signals appeared to b

10 STAT protein phosphorylation is identical to IL-10 receptor activation on normal cells and similar to

11 e-treatment peptide and was reversed by anti-IL-10 receptor administration.

12 ed more IL-10 and expressed higher levels of IL-10 receptor after CD40 engagement compared to other B

13 that Treg cells possess higher expression of IL-10 receptor alpha and that Treg cell IL-10 receptor a

14 analysis of the intracellular domain of the IL-10 receptor alpha chain showed that whereas two redun

15 n of IL-10 receptor alpha and that Treg cell IL-10 receptor alpha expression directly correlates with

16 IL-10 receptor alpha is highly enriched in mature adipoc

17 vealed that the epithelial anti-inflammatory IL-10 receptor alpha subunit (IL-10RA) is also important

18 protein 3 (FOXP3), CD40 ligand (CD40L), and IL-10 receptor alpha(IL10RA), as well as patients with t

19 ore rapidly in the presence of an anti-human IL-10 receptor-alpha antibody, and efferocytosis by IL-1

20 cmvIL-10 can bind to the human IL-10 receptor and can compete with human IL-10 for bind

21 e IL-2 receptor gamma(IL2RG) gene as well as IL-10 receptor and CD40 ligand deficiencies had normal o

22 , designated cmvIL-10, binds to the cellular IL-10 receptor and effects potent immune suppression.

23 xtracellular domain of the recombinant human IL-10 receptor and IL-10 is consistent with two IL-10 ho

24 IL-10 provides neuroprotection by acting via IL-10 receptor and PI3K/AKT and STAT-3 signal transducti

25 That the duration of IL-10 receptor and STAT3 activation can direct distinct

26 The IL-10 receptor and the IL-2 receptor gammac chain were a

27 We set out to map the human IL-10 receptor and to identify the key elements involved

28 (+) T cells expressed elevated levels of the IL-10 receptor and were directly activated by IL-10, res

29 fects were specifically mediated through the IL-10 receptor and were not observed when DCs were treat

30 s the interferon receptors, the interleukin (IL) 10 receptor, and tissue factor.

31 ssors of cytokine signaling proteins (SOCS), IL-10 receptor, and galectin-7.

32 he overexpression of interleukin-10 (IL-10), IL-10 receptor, and suppressor of cytokine signaling (SO

33 ansiently during the chronic phase with anti-IL-10 receptor antibodies achieved sterile cure, suggest

34 vention with neutralizing anti-IL-10 or anti-IL-10 receptor antibodies.

35 nositide 3-kinase (PI3K) inhibitor, and anti-IL-10 receptor antibody revealed that the PI3K pathway i

36 Blockade of IL-10 signaling with anti-IL-10 receptor antibody reversed the age-related decay.

37 e anti-inflammatory effects of IL-37 because IL-10-receptor antibody blockade did not reverse IL-37-m

38 class II cytokine receptor that consisted of IL-10 receptor beta (IL-10Rbeta) and an orphan class II

39 lymorphism (A/G) at cDNA position 238 of the IL-10 receptor beta gene (IL10RB/c238) was genotyped in

40 present study, we examined variation in the IL-10 receptor beta gene as a further test of the hypoth

41 increased 6.5-fold and minimal responses to IL-10 receptor blockade suggested downregulated IL-10.

42 ice, migration assays, and antibody-mediated IL-10 receptor blockade to study plasmacytosis-associate

43 ion in the airways, which was reversed after IL-10 receptor blockade.

44 reduced in vaccinia virus-treated mice with IL-10 receptor blockade.

45 cytokine-inhibited mice were treated with an IL-10 receptor blocking antibody and a TLR-9 agonist, an

46 lygyrus-induced T1D protection, nor did anti-IL-10 receptor blocking antibody.

47 t not IL-10(-/-) BMDCs, a process blocked by IL-10 receptor blocking antibody.

48 sponses are enhanced in the presence of anti-IL-10 receptor-blocking Abs or on the removal of CD14+ c

49 esistance because its neutralization with an IL-10 receptor-blocking monoclonal antibody allowed accu

50 s directly recruited to the ligand-activated IL-10 receptor by binding to specific but redundant rece

51 The IL-10 receptor chains, IL-10R1 and IL-10R2, are expresse

52 an accessory chain essential for the active IL-10 receptor complex and to initiate IL-10-induced sig

53 cmvIL-10 requires both subunits of the IL-10 receptor complex to induce signal transduction eve

54 on the JAK2 pathway and found that the IL-10/IL-10 receptor complex up-regulated JAK2 signaling.

55 CRF2-9 and IL-10R2, the second chain of the IL-10 receptor complex.

56 IL-10 receptor-deficient (Il10rb(-/-)) T(reg) cells also

57 r mice (VertX), cell-type-specific IL-10 and IL-10 receptor deletion mice, and bone marrow chimeric m

58 , we demonstrated that transient blockade of IL-10 receptor during the T cell priming phase early in

59 Ligand binding and activation of the IL-10 receptor expressed on B-CLL cells results in the p

60 Human IgG suppressed IL-10 receptor expression and altered IL-10 signaling in

61 f inhibition involved decreased cell surface IL-10 receptor expression and Jak1 activation and was de

62 We propose that CD8(+) T cells increase DRG IL-10 receptor expression and that IL-10 suppresses the

63 Paclitaxel increased DRG IL-10 receptor expression and this effect requires CD8(+

64 est that to optimize TR1 cell-based therapy, IL-10 receptor expression has to be taken into considera

65 In contrast, loss of IL-10 receptor expression impaired the critical conditio

66 tudy, we undertook a biochemical analysis of IL-10 receptor expression on freshly isolated B-CLL cell

67 es compared with control monocytes, although IL-10 receptor expression was similar in SLE and control

68 Using the examples of the IL-6 and IL-10 receptors, I will discuss how diverse outcomes in

69 infection in normal mice, anti-interleukin (IL)-10 receptor (IL-10R) monoclonal antibody (MAb) treat

70 oblot analysis was preformed to identify the IL-10 receptor (IL-10R) and phosphorylated or nonphospho

71 Monogenic interleukin-10 (IL-10) and IL-10 receptor (IL-10R) deficiencies cause very early on

72 We also observed internalization of the IL-10 receptor (IL-10R) in mucosal lymphocytes, which co

73 Inherited deficiencies of IL-10 or IL-10 receptor (IL-10R) lead to immune dysregulation wit

74 IL-10 blockade in vitro with anti-IL-10 receptor (IL-10R) monoclonal antibody restored LPM

75 ulated with Helicobacter hepaticus plus anti-IL-10 receptor (IL-10R) monoclonal antibody was exacerba

76 0 within tumors, and therapeutic blockade of IL-10 receptor (IL-10R) was equivalent to CSF-1 neutrali

77 In vivo blockade of the IL-10 receptor (IL-10R) with a neutralizing antibody res

78 Blockade of IL-10 receptor (IL-10R) with an antagonist antibody dram

79 ection upregulated IL-10R1, a subunit of the IL-10 receptor (IL-10R), and also SOCS3, a negative regu

80 ated mice with a DC-specific deletion of the IL-10 receptor (IL-10R).

81 a negative feedback mechanism involving the IL-10 receptor (IL-10R).

82 ically, we generated mice harboring IL-10 or IL-10 receptor (IL-10Ralpha) mutations in intestinal lam

83 Blockade of IL-10 receptor in Bhlhe40(-/-) mice renders them suscept

84 Ablation of the IL-10 receptor in Treg cells resulted in selective dysre

85 4(+) T cells differentially express IL-6 and IL-10 receptors in an activation state-dependent manner,

86 In contrast, an antagonistic antibody to the IL-10 receptor increased LPS-induced hepatomegaly by as

87 duction requires two distinct regions of the IL-10 receptor intracellular domain and thereby establis

88 Stat3, Jak1, and two distinct regions of the IL-10 receptor intracellular domain.

89 an integral membrane protein or is bound to IL-10 receptors is not yet known.

90 The interleukin-10 (IL-10) receptor is another member of the IFN receptor fa

91 , IL-10R1, the ligand-binding subunit of the IL-10 receptor, is predominantly expressed by TNF-produc

92 These results suggest complex regulation of IL-10 receptor-ligand interactions and subsequent biolog

93 Last, mice with muscle-specific ablation of IL-10 receptor (M-IL10R(-/-)) were generated to determin

94 it to evade host immune reactions through an IL-10 receptor mediated immune-suppression pathway.

95 is associated with the induction of cellular IL-10 receptor-mediated signaling pathways.

96 vIL-10His6, with recombinant mouse and human IL-10 receptors (mIL-10R, hIL-10R).

97 We found that the cells expressed IL-10 receptor mRNA, suggesting that autocrine effects a

98 presence on the intracellular domain of the IL-10 receptor of a carboxyl-terminal sequence containin

99 ding functional evidence for the presence of IL-10 receptors on CD4(+) T cells.

100 Treatment with anti-IL-10-receptor or anti-CD25 antibody enhanced early para

101 oduction in lesions, and blocking the murine IL-10 receptor prevented antibody-mediated disease exace

102 -339) peptide antigen, together with an anti-IL-10 receptor (R) mAb led to the enhancement of a Th1 r

103 t with a functional blocking antibody to the IL-10 receptor reduced both Stat-3 and AKT phosphorylati

104 dministration of an antibody that blocks the IL-10 receptor restored T-cell function and eliminated v

105 onstrate that the CRFB4 chain is part of the IL-10 receptor signaling complex.

106 TR1 cells with impaired IL-10 receptor signaling lost their regulatory activity

107 ese events were prevented by either blocking IL-10 receptor signaling or inhibiting proteasome degrad

108 TR1 cells required IL-10 receptor signaling to activate p38 MAPK, thereby s

109 mice and transgenic mice with impairment in IL-10 receptor signaling were used to test the activity

110 TR1 cell regulatory activity is dependent on IL-10 receptor signaling.

111 t specificity and express between 47 and 127 IL-10 receptor sites per cell, with a dissociation const

112 ansgenic mice expressing a dominant-negative IL-10 receptor specifically in T cells (CD4dnIL-10Ralpha

113 hat muscle cells in mdx muscle expressed the IL-10 receptor, suggesting that IL-10 could have direct

114 od dendritic cells were found to express the IL-10 receptor, suggesting that IL-10 may directly act o

115 in binding of one or more components of the IL-10 receptor system, and thus the structural differenc

116 different molecular mechanisms to engage the IL-10 receptors that ultimately enhance the respective a

117 ) protein recruitment to the interleukin 10 (IL-10) receptor, the STAT proteins activated by IL-10 in

118 ertheless, the signaling pathway used by the IL-10 receptor to generate the anti-inflammatory respons

119 7) in the intracellular domain of the murine IL-10 receptor were found to be redundantly required for

120 human IL-6, vIL-6, human IL-10, and soluble IL-10 receptor were used.